<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803630</url>
  </required_header>
  <id_info>
    <org_study_id>I 79318</org_study_id>
    <secondary_id>NCI-2021-01102</secondary_id>
    <secondary_id>I 79318</secondary_id>
    <nct_id>NCT04803630</nct_id>
  </id_info>
  <brief_title>Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study</brief_title>
  <official_title>Survivor Warming to Alter Mood (S-WARM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial evaluates the effect of thermal therapy on depression with or&#xD;
      without sleep disturbance in cancer survivors. Thermal therapy may help improve quality of&#xD;
      life, physical capacity, fatigue, and enhance positive mood and sleep quality. The purpose of&#xD;
      this study is to evaluate the potential of thermal therapy to improve patient's quality of&#xD;
      life by reducing symptoms of depression, sleep disruption, fatigue and anxiety in cancer&#xD;
      survivors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the potential of thermal therapy to improve quality of life by reducing&#xD;
      symptoms of depression in cancer survivors.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the potential of thermal therapy to improve quality of life by reducing&#xD;
      symptoms of sleep disruption in cancer survivors.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the potential of thermal therapy to improve quality of life by reducing&#xD;
      symptoms of fatigue, anxiety and other generally debilitating aspects of increased stress in&#xD;
      cancer survivors.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo thermal therapy over 2.5 hours.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at weeks 1 or 2, 3 or 4, and&#xD;
      then monthly for months 2-4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Awaiting grant funding for next phase of study&#xD;
  </why_stopped>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">May 6, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 6, 2026</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in depression</measure>
    <time_frame>Baseline to 1 or 2 weeks after completion of therapy</time_frame>
    <description>Measured by the Hamilton Depression Rating Scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durability of and variability in the response over time</measure>
    <time_frame>Up to 4 months after completion of therapy</time_frame>
    <description>Hypothesis tests of mixed effect model fixed effect slope parameters representing the population averaged changes in HDRS over time will be used to investigate whether the thermal intervention effects are durable over the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pittsburgh Sleep Quality Index scores</measure>
    <time_frame>Baseline, up to 4 months</time_frame>
    <description>A 19 self-rated questionnaire. Each item is weighted on a 0-3 interval scale where lower scores denote a healthier sleep quality.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment of depression (thermal therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo thermal therapy over 2.5 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment of depression (thermal therapy)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment of depression (thermal therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thermotherapy</intervention_name>
    <description>Undergo thermal therapy</description>
    <arm_group_label>Treatment of depression (thermal therapy)</arm_group_label>
    <other_name>Heat Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have had therapy for malignancy&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of =&lt; 2&#xD;
&#xD;
          -  Patient or legal representative must understand the investigational nature of this&#xD;
             study and sign an Independent Ethics Committee/Institutional Review Board approved&#xD;
             written informed consent form prior to receiving any study related procedure&#xD;
&#xD;
          -  Patient denies current pregnancy&#xD;
&#xD;
          -  Patients who screen positive on the depression/anxiety domain will be given the&#xD;
             Hamilton Depression Rating Scale. Those with a score of 16 or more on this scale will&#xD;
             be eligible for intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of prior myocardial infarction. These patients may be allowed with clearance&#xD;
             from a cardiologist&#xD;
&#xD;
          -  History of any condition deemed by the principal investigator to be a contraindication&#xD;
             to S-WARM therapy (e.g., skin reaction, dysregulation of thermoregulation, etc.)&#xD;
&#xD;
          -  All patients with transdermal patches (e.g.; fentanyl, Lidoderm, scopolamine, etc.)&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Any condition which in the Investigator's opinion deems the patient an unsuitable&#xD;
             candidate to receive S-WARM&#xD;
&#xD;
          -  Received an investigational agent within 30 days prior to enrollment&#xD;
&#xD;
          -  Uncontrolled concurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Patients on dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anurag K Singh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

